Mainz Biomed N.V. (MYNZ) - חוב לטווח ארוך להון

This market valuation chart for Mainz Biomed N.V. (MYNZ) on the GURU.Markets platform demonstrates the 0.46 metric. The business relies on unique patents for detecting fecal oncological markers and significant investments in method verification, which hinders competitor expansion under strict FDA oversight. The integration of diagnostic solutions into medical protocols makes them indispensable for prevention. Meanwhile, expansion in the US depends on regulators, whereas European laboratories are already tied to Mainz Biomed N.V. (MYNZ) PCR technologies.

The implementation of robotic cancer diagnostic systems requires significant capital expenditures in laboratory automation. This indicator measures the proportion of long-term liabilities relative to equity, determining the degree of financial autonomy for Mainz Biomed N.V. (MYNZ). A low metric value minimizes bankruptcy risks during the long-term financing of innovations. This allows the investor to assess the stability of the liability structure. The dynamics of these processes are reflected in the history of the long-term debt-to-equity ratio.